The DropJuly 3, 2026via The Verge AI
Anthropic wants to develop its own drugs
Why it matters
Anthropic is vertically integrating beyond AI infrastructure into pharmaceutical R&D, launching Claude Science as a specialized workbench for drug discovery. This signals a major shift: AI labs are no longer just selling models—they're using them to enter adjacent high-value industries.
Key signals
- Anthropic launches Claude Science, an AI workbench for scientists integrating fragmented tools and datasets
- Platform generates figures and visuals for scientific research
- Anthropic announced plans to develop its own drugs—moving beyond tools into pharma applications
- Anthropic already has biotech and pharma customers using Claude
- Event: 'The Briefing: AI for Science' where announcement was made
- Framed around accelerating scientific discovery and healthcare intervention development
The hook
Anthropic just shipped Claude Science. Now it's building drugs.
At the event "The Briefing: AI for Science" earlier this week, Anthropic announced Claude Science, a new "AI workbench for scientists" that pulls fragmented tools and datasets into one environment, and generates figures and visuals. Anthropic, already dominating the industry with its popular coding tools and powerful AI models, framed the launch around what it says is AI's potential to "dramatically accelerate the pace of scientific discovery and the development of healthcare interventions," and touted a long list of biotech and pharma customers already using Claude.
Anthropic also went a step further, saying it would develop drugs of its …
Read the full story at The Verge.